Close

ContraFect (CFRX) Begins Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia

May 25, 2017 7:06 AM EDT Send to a Friend
ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login